Format:
11
ISSN:
1556-1380
Content:
The hepatocyte growth factor receptor mesenchymal-epithelial transition (MET) is reported to be a negative prognostic marker in EGFR-mutant NSCLC and involved in resistance to EGFR inhibitors. Emibetuzumab, a humanized immunoglobulin G4 monoclonal bivalent MET antibody, blocks ligand-dependent and ligand-independent hepatocyte growth factor/MET signaling. This phase 2 study compared erlotinib with and without emibetuzumab in first-line treatment of EGFR-mutant metastatic NSCLC.
Note:
Available online - 14 October 2019
,
Gesehen am 11.03.2020
In:
Journal of thoracic oncology, Amsterdam : Elsevier, 2006, 15(2020), 1, Seite 80-90, 1556-1380
In:
volume:15
In:
year:2020
In:
number:1
In:
pages:80-90
In:
extent:11
Language:
English
DOI:
10.1016/j.jtho.2019.10.003
URL:
Volltext
(lizenzpflichtig)
URL:
Volltext
(lizenzpflichtig)
Bookmarklink